The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease
Alzheimer's & Dementia · 2026-10 · 22 (10)
DOI: 10.1002/alz.71819 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.10.2026. Verfasst von Jack M Chapel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sol Price School of Public Policy, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, USC Schaeffer Center for Health Policy & Economics, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression by 29% over individuals’ remaining lifetime (baseline mean age: 73.0); earlier treatment initiated 2 years earlier. RESULTS Treatment generated $104,885 (95% CI: $99,291, $110,479) in gross societal value over an individual's lifetime, including quality‐of‐life gains, reduced caregiving burden, and medical cost offsets driven by reduced nursing home use and Medicaid spending. Earlier treatment increased value 32%; this rose to 71% if treatment effects are also stronger (36% slowing) in earlier AD stages. Scenarios with 4‐year effect duration yielded $49,122 (treatment) and $56,385 (earlier treatment). DISCUSSION Timely treatment consistently increased long‐term societal value. The findings provide a benchmark against which treatment implementation costs can be weighed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sol Price School of Public Policy, University of Southern California, Los Angeles, California, USA.
- Leonard D. Schaeffer Institute for Public Policy and Government Service, University of Southern California, Los Angeles, California, USA.
- Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
- Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
ORCID-Profile: Jack M Chapel
Förderung
- NIA NIH HHS
- USC Schaeffer Center for Health Policy & Economics
- National Institute on Aging
Zitieren
APA
Chapel, J. M., Tysinger, B., Pourmand, H., Goldman, D., Aisen, P., & Alzheimer's Disease Neuroimaging Initiative (2026). The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease. Alzheimer's & Dementia, 22(10). https://doi.org/10.1002/alz.71819
Vancouver
Chapel JM, Tysinger B, Pourmand H, Goldman D, Aisen P, Alzheimer's Disease Neuroimaging Initiative. The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease. Alzheimer's & Dementia. 2026;22(10). doi:10.1002/alz.71819
BibTeX
@article{Chapel2026,
author = {Chapel, Jack M and Tysinger, Bryan and Pourmand, Hossein and Goldman, Dana and Aisen, Paul and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {10},
doi = {10.1002/alz.71819}
}
EUVIMED